AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma

DISEASE CHARACTERISTICS: Histologically or cytologically confirmed advanced solid tumors or lymphoma Must have measurable disease outside a previously irradiated field OR regrowth of tumor within a previously irradiated field Must be a candidate for gemcitabine hydrochloride treatment, in the opinion of the investigator No untreated or symptomatic brain metastases No tumors with direct bowel invasion No other hematological malignancies No non-small cell lung cancer of squamous cell histology or large central tumor (lesions ≥ 3 cm and located adjacent to or within the hilum or mediastinum) PATIENT CHARACTERISTICS: ECOG performance status 0-2 Not pregnant No nursing during and for 6 months after completion of study treatment Fertile patients must use effective contraception during and for 6 months after completion of study treatment Negative pregnancy test Able to swallow oral medication Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9 g/dL Creatinine ≤ 2.0 mg/dL OR creatinine clearance ≥ 40 mL/min Albumin-adjusted calcium ≥ 8 mg/dL Urine protein < 30 mg/dL by urinalysis or < 1+ by dipstick OR < 500 mg by 24-hour urine collection AST or ALT ≤ 2.5 times upper limit of normal (ULN) (5.0 times ULN in the presence of liver metastasis or primary hepatic neoplasm) Bilirubin ≤ 2 times ULN PT ≤ 2.0 INR or PTT ≤ 1.5 times ULN Systolic blood pressure (BP) ≤ 145 mm Hg and diastolic BP ≤ 85 mm Hg (stable antihypertensive medication allowed) No myocardial infraction within the past year No arterial thrombosis or deep vein thrombosis within the past year No unstable angina No congestive heart failure No New York Heart Association class III-IV cardiac disease No other unstable or uncontrolled disease or condition relating to or impacting cardiac function No HIV positivity No other condition that would preclude study participation, compliance, or follow-up assessments PRIOR CONCURRENT THERAPY: See Disease Characteristics No prior enrollment into this study At least 1 month since prior investigational device or drug trial At least 1 month since prior major surgical procedure At least 3 weeks since prior systemic chemotherapy At least 2 weeks since prior radiotherapy At least 2 weeks since prior rifampin or phenobarbital At least 1 week since prior treatment with any of the following: Ketoconazole Itraconazole Clarithromycin Erythromycin Cyclosporine or tacrolimus Nefazodone Herbal medications containing Hypericum perforatum (St. John's wort) At least 1 week since prior and no concurrent warfarin Concurrent prophylactic anticoagulation therapy (e.g., low-dose warfarin [≤ 2 mg/day] or low molecular weight heparin) for venous or arterial access devices allowed No prior or concurrent kinase insert domain-receptor inhibitors No concurrent chemotherapy, radiotherapy, hormone-directed cancer therapy, or tumor-directed antibody therapy Gonadotropin releasing-hormone agonist therapy allowed No concurrent interferon No concurrent grapefruit juice or whole grapefruit No other concurrent standard or investigational drugs or antitumor treatment, including c-kit, platelet-derived growth factor, vascular endothelial growth factor, or epidermal growth factor inhibitors No elective surgery during or for 2 weeks after completion of the last dose of AMG 706